The Food and Drug Administration Friday approved the first biosimilar to treat neovascular age-related macular degeneration, a leading cause of vision loss and blindness for seniors. The biosimilar (Byooviz) also was approved to treat fluid build-up following vein blockage in the retina and myopic choroidal neovascularization, a vision-threatening complication of nearsightedness. 

“Continuing to grow the number of biosimilar approvals is a key part of our efforts to provide greater access to treatment options for patients, increase competition and potentially lower costs,” said Sarah Yim, M.D., who directs the Office of Therapeutic Biologics and Biosimilars in FDA’s Center for Drug Evaluation and Research.
 

Related News Articles

Headline
The Food and Drug Administration today approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Food and Drug Administration and Magellan Diagnostics Inc. today expanded the ongoing recall of LeadCare II, LeadCare Plus and LeadCare Ultra Blood Lead…
Headline
The Food and Drug Administration today announced it will withdraw regulations for non-drug manufacturers who produced during the COVID-19 public health…
Headline
DeRoyal Industries recently recalled more than 2,800 procedure packs distributed in the U.S. that could expose patients to harmful levels of aluminum. The…
Headline
The Food and Drug Administration yesterday authorized the emergency use of a new over-the-counter COVID-19 antigen test. Unlike most antigen tests for at-…